Literature DB >> 22446121

Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms.

Haiyang Zhao1, Keiji Nakamura, Tomoko Kohda, Masafumi Mukamoto, Shunji Kozaki.   

Abstract

Clostridium botulinum produces large complex toxins, which include botulinum neurotoxin (BoNT) and auxiliary non-toxic proteins. We prepared monoclonal antibodies (mAbs) from mice that were immunized several times with BoNT/A after basal immunization with toxoid. We then examined the reactivities of these mAbs to BoNT and toxoid and showed that some mAbs reacted to only BoNT. This result indicates that the antigenicity of BoNT/A partially disappeared with formalin treatment. Some mAbs that specifically recognized either BoNT/A1 or BoNT/A2 were considered useful as detection antibodies specific for the BoNT/A subtype. Results of a neutralizing test with mAbs against either BoNT/A1 or BoNT/A2 showed that neutralizing antibody recognition sites were present in the light chain, heavy chain (N-terminal half), and heavy chain (C-terminal half) domains. Investigation of the different binding capabilities of the mAbs to BoNT and the complex toxin by immunoprecipitation suggested that the light chain of BoNT is exposed at the molecular surface of the complex toxin since there was no difference in the binding of light chain-specific mAb to BoNT and the complex toxin. The heavy chain is related to BoNT binding to non-toxic components, because the reactivity of the heavy chain to some mAbs was influenced by non-toxic components.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22446121

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  5 in total

1.  High level expression, purification and immunogenicity analysis of a protective recombinant protein against botulinum neurotoxin type E.

Authors:  Ebrahim Valipour; Mir-Latif Moosavi; Jafar Amani; Shahram Nazarian
Journal:  World J Microbiol Biotechnol       Date:  2014-01-29       Impact factor: 3.312

2.  Immunogenicity evaluation of rBoNT/E nanovaccine after mucosal administration.

Authors:  Mohamad Javad Bagheripour; Firouz Ebrahimi; Abbas Hajizade; Shahram Nazarian
Journal:  Iran J Basic Med Sci       Date:  2019-04       Impact factor: 2.699

3.  Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice.

Authors:  Svetlana A Godakova; Anatoly N Noskov; Irina D Vinogradova; Galina A Ugriumova; Andrey I Solovyev; Ilias B Esmagambetov; Amir I Tukhvatulin; Denis Y Logunov; Boris S Naroditsky; Dmitry V Shcheblyakov; Aleksandr L Gintsburg
Journal:  Toxins (Basel)       Date:  2019-08-07       Impact factor: 4.546

4.  Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations.

Authors:  Eran Diamant; Bat-El Lachmi; Adi Keren; Ada Barnea; Hadar Marcus; Shoshana Cohen; Alon Ben David; Ran Zichel
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

5.  Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin.

Authors:  B Vijayalakshmi Ayyar; Rajeev B Tajhya; Christine Beeton; M Zouhair Atassi
Journal:  Sci Rep       Date:  2015-10-28       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.